Fulgent Genetics Analyst Ratings
Fulgent Genetics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/18/2022 | 25.38% | Raymond James | → $45 | Initiates Coverage On | → Outperform |
| 11/14/2022 | 39.31% | Credit Suisse | $65 → $50 | Maintains | Outperform |
| 11/14/2022 | 81.11% | Piper Sandler | $70 → $65 | Maintains | Overweight |
| 08/25/2022 | 81.11% | Credit Suisse | → $65 | Initiates Coverage On | → Outperform |
| 05/16/2022 | 95.04% | Piper Sandler | $85 → $70 | Maintains | Overweight |
| 01/25/2022 | 248.29% | Oppenheimer | $141 → $125 | Maintains | Outperform |
| 08/10/2021 | 81.11% | Credit Suisse | $55 → $65 | Maintains | Underperform |
| 03/05/2021 | 290.08% | Piper Sandler | $135 → $140 | Maintains | Overweight |
| 02/01/2021 | 262.22% | Oppenheimer | $75 → $130 | Maintains | Outperform |
| 01/08/2021 | — | Credit Suisse | Downgrades | Neutral → Underperform | |
| 11/24/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/25/2020 | 17.02% | Credit Suisse | $13 → $42 | Maintains | Neutral |
| 08/20/2020 | 108.97% | Oppenheimer | → $75 | Initiates Coverage On | → Outperform |
| 07/27/2020 | -13.62% | Piper Sandler | $21 → $31 | Maintains | Overweight |
| 06/17/2020 | -41.49% | Piper Sandler | $18 → $21 | Maintains | Overweight |
| 05/29/2020 | -44.27% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/05/2020 | -69.35% | Credit Suisse | $12 → $11 | Maintains | Neutral |
| 11/05/2019 | -65.73% | Piper Sandler | $9.5 → $12.3 | Upgrades | Neutral → Overweight |
| 04/26/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
| 05/09/2018 | -86.07% | Credit Suisse | $6 → $5 | Maintains | Outperform |
| 03/01/2018 | — | Piper Sandler | Downgrades | Overweight → Neutral | |
| 03/01/2018 | -83.28% | Credit Suisse | $6.5 → $6 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/18/2022 | 25.38% | 雷蒙德·詹姆斯 | → $45 | 開始承保 | →跑贏大盤 |
| 11/14/2022 | 39.31% | 瑞士信貸 | $65 → $50 | 維護 | 跑贏大盤 |
| 11/14/2022 | 81.11% | 派珀·桑德勒 | $70 → $65 | 維護 | 超重 |
| 08/25/2022 | 81.11% | 瑞士信貸 | → $65 | 開始承保 | →跑贏大盤 |
| 05/16/2022 | 95.04% | 派珀·桑德勒 | $85 → $70 | 維護 | 超重 |
| 01/25/2022 | 248.29% | 奧本海默 | $141 → $125 | 維護 | 跑贏大盤 |
| 08/10/2021 | 81.11% | 瑞士信貸 | $55 → $65 | 維護 | 表現不佳 |
| 03/05/2021 | 290.08% | 派珀·桑德勒 | $135 → $140 | 維護 | 超重 |
| 02/01/2021 | 262.22% | 奧本海默 | $75 → $130 | 維護 | 跑贏大盤 |
| 01/08/2021 | — | 瑞士信貸 | 評級下調 | 中性→表現不佳 | |
| 11/24/2020 | — | BTIG | 評級下調 | 購買→中性 | |
| 09/25/2020 | 17.02% | 瑞士信貸 | $13 → $42 | 維護 | 中性 |
| 08/20/2020 | 108.97% | 奧本海默 | → $75 | 開始承保 | →跑贏大盤 |
| 07/27/2020 | -13.62% | 派珀·桑德勒 | $21 → $31 | 維護 | 超重 |
| 06/17/2020 | -41.49% | 派珀·桑德勒 | $18 → $21 | 維護 | 超重 |
| 05/29/2020 | -44.27% | BTIG | → $20 | 開始承保 | →購買 |
| 05/05/2020 | -69.35% | 瑞士信貸 | $12 → $11 | 維護 | 中性 |
| 11/05/2019 | -65.73% | 派珀·桑德勒 | $9.5 → $12.3 | 升級 | 中性→超重 |
| 04/26/2019 | — | 瑞士信貸 | 評級下調 | 跑贏→中性 | |
| 05/09/2018 | -86.07% | 瑞士信貸 | $6 → $5 | 維護 | 跑贏大盤 |
| 03/01/2018 | — | 派珀·桑德勒 | 評級下調 | 超重→中性 | |
| 03/01/2018 | -83.28% | 瑞士信貸 | $6.5 → $6 | 維護 | 跑贏大盤 |
What is the target price for Fulgent Genetics (FLGT)?
Fulgent Genetics(FLGT)的目標價是多少？
The latest price target for Fulgent Genetics (NASDAQ: FLGT) was reported by Raymond James on November 18, 2022. The analyst firm set a price target for $45.00 expecting FLGT to rise to within 12 months (a possible 25.38% upside). 6 analyst firms have reported ratings in the last year.
雷蒙德·詹姆斯於2022年11月18日報道了富金特遺傳公司(納斯達克代碼：FLGT)的最新目標價。這家分析公司將目標價定為45.00美元，預計FLGT將在12個月內上漲(可能上漲25.38%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Fulgent Genetics (FLGT)?
富力遺傳(Fulgent Genetics)最新的分析師評級是多少？
The latest analyst rating for Fulgent Genetics (NASDAQ: FLGT) was provided by Raymond James, and Fulgent Genetics initiated their outperform rating.
富力遺傳(納斯達克股票代碼：FLGT)的最新分析師評級由Raymond James提供，富力遺傳啟動了他們的表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Fulgent Genetics (FLGT)?
Fulgent Genetics(FLGT)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulgent Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulgent Genetics was filed on November 18, 2022 so you should expect the next rating to be made available sometime around November 18, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Fulgent Genetics的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Fulgent Genetics的上一次評級是在2022年11月18日提交的，所以你應該預計下一次評級將在2023年11月18日左右的某個時候公佈。
Is the Analyst Rating Fulgent Genetics (FLGT) correct?
分析師對Fulgent Genetics(FLGT)的評級正確嗎？
While ratings are subjective and will change, the latest Fulgent Genetics (FLGT) rating was a initiated with a price target of $0.00 to $45.00. The current price Fulgent Genetics (FLGT) is trading at is $35.89, which is within the analyst's predicted range.
雖然評級是主觀的，並會發生變化，但最新的Fulgent Genetics(FLGT)評級是以0.00美元至45.00美元的目標價啟動的。富爾金特基因公司目前的股價為35.89美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。